Literature DB >> 11081163

Surgical management of thyrotropin-secreting pituitary adenomas.

M Losa1, P Mortini, A Franzin, R Barzaghi, C Mandelli, M Giovanelli.   

Abstract

The reported cases of hyperthyroidism due to a TSH-secreting pituitary adenoma have steadily increased in previous years; however, information about the results and long term outcome after pituitary surgery is scanty. Twenty-four patients with a TSH-secreting adenoma underwent pituitary surgery at our department in the last 15 years. Hypersecretion of other pituitary hormones was diagnosed in 7 patients. Three patients were euthyroid at the time of surgery because of previous ablative thyroid therapies. The success rate of surgery strictly depends on the criteria used. Normalization of elevated FT3 and FT4 levels occurred in 17 of the 21 patients with preoperative hyperthyroidism: however, only those with early postoperative undetectable TSH level (12 cases) had no recurrence of disease during follow-up and no residual tumor tissue on postoperative MRI, whereas recurrence of hyperthyroidism occurred in 3 of the 5 patients without postoperative TSH inhibition. All 3 euthyroid patients had a subtotal removal of the tumor, as judged by postoperative MRI. Surgical removal is the therapy of choice of TSH-secreting adenomas, whereas radiotherapy and medical treatment with somatostatin analogues are usually reserved to patients with incomplete tumor removal. A thorough postoperative evaluation is necessary to discriminate between complete and partial remission of disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11081163     DOI: 10.1023/a:1009987530852

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  14 in total

1.  Surgical treatment of thyrotropin-secreting pituitary adenomas.

Authors:  I E McCutcheon; B D Weintraub; E H Oldfield
Journal:  J Neurosurg       Date:  1990-11       Impact factor: 5.115

2.  Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels.

Authors:  M Losa; P Magnani; P Mortini; L Persani; S Acerno; E Giugni; C Songini; F Fazio; P Beck-Peccoz; M Giovanelli
Journal:  Eur J Nucl Med       Date:  1997-07

Review 3.  The syndromes of resistance to thyroid hormone.

Authors:  S Refetoff; R E Weiss; S J Usala
Journal:  Endocr Rev       Date:  1993-06       Impact factor: 19.871

4.  Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas.

Authors:  M Losa; M Giovanelli; L Persani; P Mortini; G Faglia; P Beck-Peccoz
Journal:  J Clin Endocrinol Metab       Date:  1996-08       Impact factor: 5.958

5.  Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.

Authors:  A Gancel; P Vuillermet; A Legrand; F Catus; F Thomas; J M Kuhn
Journal:  Clin Endocrinol (Oxf)       Date:  1994-03       Impact factor: 3.478

6.  Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.

Authors:  J Bertherat; T Brue; A Enjalbert; G Gunz; R Rasolonjanahary; A Warnet; P Jaquet; J Epelbaum
Journal:  J Clin Endocrinol Metab       Date:  1992-08       Impact factor: 5.958

7.  Thyrotropin-producing microadenoma associated with pituitary resistance to thyroid hormone.

Authors:  K Watanabe; T Kameya; A Yamauchi; N Yamamoto; A Kuwayama; I Takei; H Maruyama; T Saruta
Journal:  J Clin Endocrinol Metab       Date:  1993-04       Impact factor: 5.958

Review 8.  The variable clinical phenotype in thyroid hormone resistance syndrome.

Authors:  P Beck-Peccoz; V K Chatterjee
Journal:  Thyroid       Date:  1994       Impact factor: 6.568

9.  Thyroid-stimulating hormone pituitary adenomas and hyperthyroidism.

Authors:  F Grisoli; T Leclercq; J P Winteler; P Jaquet; M Guibout; P Diaz-Vasquez; J Hassoun; R Nayak
Journal:  Surg Neurol       Date:  1986-04

10.  Sex hormone-binding globulin measurement in patients with inappropriate secretion of thyrotropin (IST): evidence against selective pituitary thyroid hormone resistance in nonneoplastic IST.

Authors:  P Beck-Peccoz; R Roncoroni; S Mariotti; G Medri; C Marcocci; G Brabant; F Forloni; A Pinchera; G Faglia
Journal:  J Clin Endocrinol Metab       Date:  1990-07       Impact factor: 5.958

View more
  4 in total

Review 1.  Metabolic In Vivo Visualization of Pituitary Adenomas: a Systematic Review of Imaging Modalities.

Authors:  Amy Yao; Priti Balchandani; Raj K Shrivastava
Journal:  World Neurosurg       Date:  2017-04-28       Impact factor: 2.104

2.  Coexistence of TSH-secreting pituitary adenoma and autoimmune hypothyroidism.

Authors:  M Losa; P Mortini; R Minelli; M Giovanelli
Journal:  J Endocrinol Invest       Date:  2006-06       Impact factor: 4.256

3.  Clinical aspects and therapeutic outcome in thyrotropin-secreting pituitary adenomas: a single center experience.

Authors:  E Macchia; M Gasperi; M Lombardi; L Morselli; A Pinchera; G Acerbi; G Rossi; E Martino
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

4.  High Prevalence of Radiological Vertebral Fractures in Patients With TSH-Secreting Pituitary Adenoma.

Authors:  Stefano Frara; Marco Losa; Mauro Doga; Anna Maria Formenti; Pietro Mortini; Gherardo Mazziotti; Andrea Giustina
Journal:  J Endocr Soc       Date:  2018-07-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.